登上Nature Medicine封面：浙江大学黄河团队利用双靶点CAR-T细胞，成功治疗系统性红斑狼疮

Core Viewpoint - The article discusses the promising results of a phase 1 clinical trial that combines CD19-targeting and BCMA-targeting CAR-T cell therapies for treatment-refractory systemic lupus erythematosus (rSLE), highlighting its safety and potential clinical efficacy [3][10]. Group 1: Clinical Trial Overview - A phase 1 clinical trial was conducted to evaluate the co-infusion of CD19-targeting and BCMA-targeting CAR-T cells in rSLE patients, showing good safety and promising clinical efficacy [3][10]. - The trial involved 15 patients (14 females and 1 male) who had previously undergone lymphocyte-depleting therapy with fludarabine/cyclophosphamide [7][8]. Group 2: Safety and Efficacy Results - During a median follow-up of 712 days, no dose-limiting toxicities were reported, and 86.7% of patients experienced grade 1 cytokine release syndrome, with no neurological toxicities or treatment-related deaths [8][10]. - By week 12, 80% of patients achieved low disease activity status (LLDAS) and DORIS remission criteria, indicating significant clinical improvement [9][10]. Group 3: Mechanism and Immune Response - The study confirmed the elimination of autoreactive CD19+ BCMA+ clones and the reconstitution of initial IgM/IgD B cells, suggesting an improvement in immune homeostasis [9][10]. - Longitudinal monitoring of three patients indicated sustained eradication of pathogenic clones, suggesting potential for cure [10]. Group 4: Expert Commentary - The study received high praise from renowned rheumatology experts, emphasizing the dual-target strategy as a significant advancement in CAR-T cell therapy for systemic lupus erythematosus [10].